Key result
High FLNC expression in glioblastoma predicts ~109% worse overall survival and promotes tumor cell invasion.
Why the study?
The role of filamins, particularly filamin-C, in glioblastoma multiforme malignancy and patient prognosis is unclear.
Does high FLNC expression predict poor outcome and enhance invasiveness in glioblastoma multiforme?
Observational (n=243)
Does high FLNC expression predict poor outcome and enhance invasiveness in glioblastoma multiforme?
High FLNC expression is associated with enhanced invasiveness and poor prognosis in glioblastoma multiforme, suggesting it as a potential biomarker and therapeutic target.
Answers are grounded in this paper and cite their sources.
High FLNC may mark poor glioblastoma prognosis; leaves open biomarker or target utility pending prospective human validation.
BACKGROUND: Glioblastoma multiforme (GBM), the most common brain malignancy in adults, is generally aggressive and incurable, even with multiple treatment modalities and agents. Filamins (FLNs) are a group of actin-binding proteins that regulate the actin cytoskeleton in cells. However, the role of FLNs in malignancies-particularly in GBM-is unclear. METHODS: The relation between FLNC expression and overall survival in GBM was evaluated by the Kaplan-Meier analysis using GBM patients from the Kagoshima University Hospital (n = 90) and data from the Cancer Genome Atlas (TCGA) (n = 153). To assess FLNC function in GBM, cell migration and invasion were examined with Transwell and Matrigel invasion assays using FLNC-overexpressing U251MG and LN299 GBM cells, and ShRNA-mediated FLNC knocked-down KNS81 and U87MG cells. The gelatin zymography assay was used to estimate matrix metalloproteinase (MMP) 2 activity. RESULTS: In silico analysis of GBM patient data from TCGA and immunohistochemical analyses of clinical GBM specimens revealed that increased FLNC expression was associated with poor patient prognosis. FLNC overexpression in GBM cell lines was positively correlated with enhanced invasiveness, but not migration, and was accompanied by upregulation of MMP2. CONCLUSIONS: FLNC is a potential therapeutic target and biomarker for GBM progression.
No takes yet. Share an insight, caveat, or question.
Kamil et al. (2019) conducted an observational in Glioblastoma multiforme (n=243). High FLNC expression vs. Low FLNC expression was evaluated on Overall survival (HR 2.094, 95% CI 1.308-3.353, p=0.002). High FLNC expression in patients with glioblastoma multiforme is an independent predictor of poor overall survival (HR 2.094) and promotes tumor cell invasion.
Synapse has enriched 10 related papers. Consider them for comparative context: